WO2010003097A2 - Méthodes et dispositifs d’introduction ou de ralentissement de l’introduction des lipides dans le duodénum - Google Patents

Méthodes et dispositifs d’introduction ou de ralentissement de l’introduction des lipides dans le duodénum Download PDF

Info

Publication number
WO2010003097A2
WO2010003097A2 PCT/US2009/049586 US2009049586W WO2010003097A2 WO 2010003097 A2 WO2010003097 A2 WO 2010003097A2 US 2009049586 W US2009049586 W US 2009049586W WO 2010003097 A2 WO2010003097 A2 WO 2010003097A2
Authority
WO
WIPO (PCT)
Prior art keywords
flow reduction
reduction element
spine
duodenum
flow
Prior art date
Application number
PCT/US2009/049586
Other languages
English (en)
Other versions
WO2010003097A3 (fr
Inventor
James T. Mckinley
Zhenyong Keck
Fiona M. Sander
Original Assignee
Endosphere, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/070226 external-priority patent/WO2009012335A1/fr
Priority to EP09774546.7A priority Critical patent/EP2313034B1/fr
Priority to BRPI0915286A priority patent/BRPI0915286A2/pt
Priority to MX2010014323A priority patent/MX2010014323A/es
Priority to ES09774546.7T priority patent/ES2552821T3/es
Priority to US12/999,180 priority patent/US20110137227A1/en
Application filed by Endosphere, Inc. filed Critical Endosphere, Inc.
Publication of WO2010003097A2 publication Critical patent/WO2010003097A2/fr
Publication of WO2010003097A3 publication Critical patent/WO2010003097A3/fr
Priority to HK11111552.4A priority patent/HK1157252A1/xx
Priority to US13/769,097 priority patent/US9072861B2/en
Priority to US14/793,454 priority patent/US20150305906A1/en
Priority to US15/384,130 priority patent/US20170156908A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013—Implantable devices or invasive measures
    • A61F5/0076—Implantable devices or invasive measures preventing normal digestion, e.g. Bariatric or gastric sleeves
    • A61F5/0079—Pyloric or esophageal obstructions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/50—Prostheses not implantable in the body
    • A61F2/78—Means for protecting prostheses or for attaching them to the body, e.g. bandages, harnesses, straps, or stockings for the limb stump
    • A61F2/80—Sockets, e.g. of suction type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2002/044—Oesophagi or esophagi or gullets

Definitions

  • Obesity and type 2 diabetes are diseases of insufficient or deficient regulation.
  • What is needed are devices and/or methods for additional lipid uptake, delaying ingesta passage/prolonging ingesta contact, delivering or providing lipids or other appetite and glucose reducing nutrients and/or combinations of these characteristics.
  • a device adapted and configured for use within the duodenum of a mammal.
  • the device has a spine having a proximal end and a distal end; an atraumatic feature positioned on at least one of the proximal end and the distal end of the spine; and, positioned along the spine, a flow reduction element having variable porosity along its length.
  • the variable porosity of the flow reduction element is selected so that a portion of a flow over the proximal end of the flow reduction element flows into an interior portion of the flow reduction element.
  • variable porosity of the flow reduction element is selected so that flow within an interior of the flow reduction element is at least partially inhibited from flowing through the distal portion of the variable porosity structure.
  • the proximal portion of the flow reduction element comprises a material, a mesh or a braid having a porosity or altered to provide a porosity selected to permit a flow into an interior portion of the flow reduction element.
  • the distal portion of the flow reduction element comprises a material, a mesh or a braid having a porosity or altered to provide a porosity selected to at least partially inhibit a flow from within an interior portion of the flow reduction element.
  • the length of the spine is selected so when the atraumatic feature is positioned in a stomach the flow reduction element is positioned on the spine and distal to a pylorus. In one embodiment, the length of the spine is selected so when the atraumatic feature is positioned in a stomach the distal end of the spine is in the fourth portion of the duodenum and the flow reduction element is positioned within a portion of the duodenum. In one embodiment, there is also a flow reduction element having a non- variable porosity along its length. In one embodiment, there is also a feature on the spine positioned to restrict movement of the flow reduction element relative to the spine.
  • a device adapted and configured for use within the duodenum of a mammal.
  • the device has a spine with a length, a proximal end and a distal end; a first atraumatic feature positioned adjacent to the spine proximal end; a second atraumatic feature positioned adjacent to the spine distal end wherein the length of the spine is selected so that when the first atraumatic feature is in the stomach the second atraumatic feature is in the fourth portion of the duodenum; and a flow reduction element having a proximal end, a distal end, an interior portion, an exterior portion and a variable porosity between the proximal end and the distal end.
  • the porosity of the proximal end is selected to the allow flow to pass from the exterior portion to the interior portion. In one embodiment, the porosity of the distal end is selected to impede flow from the interior portion to the exterior portion, hi one embodiment, the proximal portion is more porous than the distal portion, hi one embodiment, the proximal end has a porous structure configured to permit flow into the interior portion and the distal end has a solid portion to retain material within the interior portion, hi one embodiment, there is provided another flow reduction element between the proximal and distal ends of the spine, hi one embodiment, the another flow reduction element has variable porosity between the proximal and distal ends of the flow reduction element.
  • the length of the spine is selected so that when the first atraumatic feature is positioned in a stomach the second atraumatic feature is positioned within the duodenum and adjacent to the first atraumatic feature. In one embodiment, the length of the spine is selected so that when the first atraumatic feature is positioned in a stomach the second atraumatic feature is positioned within the duodenum and in proximity to the ligament of Treitz.
  • a method for adjusting the passage of ingesta through the duodenum of a mammal by placing the distal end of a flow reduction device in the duodenum of a mammal; placing the proximal end of the flow reduction device in a stomach of the mammal; expanding within the duodenum of the mammal a variable porosity flow reduction element supported by the flow reduction device; and directing at least a portion of the flow of ingesta through the duodenum through the proximal end of the variable porosity flow reduction element and into an interior portion of the variable porosity flow reduction element.
  • a method retaining a portion of the ingesta within the interior portion of the variable porosity flow reduction element until the ingesta is pushed out of the interior portion by peristaltic action of the duodenum, hi still another embodiment, there is provided a method of adjusting the passage of ingesta wherein the ingesta is pushed out of the interior portion by passing through a distal portion of the variable porosity flow reduction element. In still another alternative method for adjusting the passage of ingesta, the ingesta is pushed out of the interior portion by passing through the proximal portion and thereafter passing around the variable porosity flow reduction element.
  • the flow reduction elements positioned along the device backbone could be coated with, manufactured from or contain lipid-philic materials.
  • one or more of the flow reduction elements of the intraduodenal device could be manufactured from a lipid absorbing or adsorbing material.
  • a flow reduction element manufactured in this way will attract and collect lipids from passing ingesta and hold the lipids for a period of time. The length of time that the lipids will remain attached to the flow reduction element will vary based on a number of factors.
  • the flow reduction element may exude the lipids as peristalsis continues to squeeze the device. The prolonged presence of and/or sustained release of lipids within the duodenum is believed to benefit and in some cases to increase hormonal regulation.
  • embodiments of the present invention provide prolonged presence of and/or sustained release of lipids within the duodenum through the use of one or more of: making flow reduction elements and/or other components of the flow reduction device (i.e., any of the components of FIG. 1 for example) at least partially or even completely from one or more lipid-philic materials; coating flow reduction elements and/or other components of the flow reduction device entirely or at least partially form lipid-philic materials; and/or placing within a flow reduction element, or attaching to a component of the flow reduction device an additional element or component formed from or at least partially coated with a lipid-philic material.
  • FIG 1 is a prospective view of a device for use in the duodenum.
  • FIG. 2 is an enlarged view of one of the flow reduction elements of FIG. 1 showing the upper and lower portions of the element;
  • FIG. 2A is an enlarged view of a material used to provide variable porosity to a flow portion of a flow reduction element
  • FIG. 2B is an enlarged view of a solid or semi permeable sheet where a pattern of holes are used to provided variable porosity to a portion of a flow reduction element;
  • FIG. 3 illustrates a flow reduction element embodiment where more of the flow reduction device is utilized for allowing flow through the use of a larger proximal portion having a more porous construction and a smaller distal portion having a less porous construction;
  • FIG. 4 illustrates a flow reduction element embodiment where more of the flow reduction device is utilized for preventing flow than for allowing flow through the use of a smaller proximal portion having a more porous construction and a larger distal portion having a less porous construction.
  • the present application relates to methods and devices for providing a sense of fullness/satiety and/or glucose production inhibition.
  • the devices and methods described herein provide for additional lipid presence in the duodenum by delaying ingesta passage/prolonging ingesta contact, delivering or providing lipids or other satiety and/or glucose reducing nutrients and/or combinations thereof.
  • Lipids can be generally defined as substances such as a fat, oil or wax that dissolve in alcohol but not in water. Lipids contain carbon, hydrogen and oxygen but have far less oxygen proportionally than carbohydrates. They serve as a source of fuel and are an important constituent of the structure of cells.
  • lipids refer to any of fatty acids, glycerides, complex lipids and nonglycerides. Fatty acids include both saturated and unsaturated.
  • Glycerides include, for example, neutral phosphoglycerides.
  • Complex lipids are lipids complexed with another type of chemical compound and include, for example, lipoproteins, phospholipids and glycolipids. Nonglycerides include, for example, sphingolipds, steroids and waxes.
  • the mesh bulges may have a more open structure on the end from which nutrients arrive from the stomach and smaller openings on the end from which nutrients depart as one way to hold nutrients longer.
  • the spheres could themselves become 'buckets' in which food is captured and retained.
  • the bucket may be provided by having a solid bottom portion so that chyme entering remains in the bottom of the bucket until pushed out by peristaltic action or my movement of additional chyme to displace it.
  • the flow restriction devices may be any of a wide variety of shapes and dimensions as described in the incorporated patent applications.
  • the adjustment of the flow characteristics of ingesta or chyme: (a) around the outside of a flow reduction element, (b) through a wall of a flow or portion of a flow reduction element and (c) retained within a flow reduction element may be accomplished in a number of ways.
  • One way to adjust the flow characteristics within a flow regulated duodenum i.e., a duodenum having a flow reduction device implanted within it
  • FIG. 1 illustrates a perspective view of a device 100 having a spine 105, a proximal end 110, a distal end 115, atraumatic features 120 on both the proximal and distal ends.
  • a series of five flow reduction elements 130 are shown in position along the spine 105.
  • the flow reduction elements 130 are shown in a deployed configuration as they would be in use within the duodenum.
  • one or more of the flow reduction elements may be formed from a material or materials with porosity characteristics that adjust the flow characteristics of chyme or ingesta flow relative to the material and the flow reduction element.
  • the device 100 is orientated as it would be implanted with the proximal end 110 in the stomach and the distal end 115 in the duodenum near the ligament of Trietz. Chyme/ingesta flow is from the proximal end 110 to the distal end 115 in FIG. 1.
  • the more porous portion of the flow reduction element 140 will interact with the chyme first. Because of the porosity of this part of the flow reduction element, chyme will flow into the interior portion of the flow reduction element as well as around the flow reduction element. As peristaltic action in the duodenum continues to move the chyme, the portion inside of the flow reduction element is urged distally towards the portion of the flow reduction device that is less porous 150.
  • Some of the chyme entering the flow reduction element portion 150 will be retained within the flow reduction element for some period of time based upon a number of factors such as how much the person has eaten and the porosity of this portion of the flow reduction element among others. As a result of the variable porosity of the structure of the flow reduction element, chyme enters but then is delayed in leaving the flow reduction element interior. It is believed that increasing the residence time of chyme within a flow reduction element will increase the time of interaction of the nutrients in that trapped portion and/or provide for an extended release of the lipids in the trapped portion of chyme.
  • the retained food could be nutrient rich or lipid rich so that the prolonged exposure produces a sense of satiety and/or the inhibition of liver glucose production in the individual.
  • FIG. 2 is an enlarged view of a flow reduction element 130 in FIG. 1.
  • the flow reduction element is divided roughly in half with an upper portion 140 (the part to first contact with the flow of chyme) having a porosity that allows flow through it and into the interior of the flow reduction element.
  • the bottom portion 150 of the flow reduction element is less porous or allows less flow of chyme from the interior of the flow reduction element.
  • the variable porosity or flow characteristics of the flow reduction elements may be adjusted by selecting material with different sizes (FIG. 2A), shapes, construction, and/or filaments with different characteristics to enhance or diminish flow as needed for the upper or lower portions.
  • the flow characteristics of a flow reduction element may be obtained by overlapping (i.e., joined or crossed without joining) filaments to form cells that will, to the desired degree, permit or impede chyme passage.
  • the flow reduction element could be formed from a solid or semipermeable sheet 160 with holes 161 formed in it as shown in FIG. 2B. The size, shape, pattern and distribution of the openings may be used to adjust the amount of relative flow through a flow reduction element.
  • the flow reduction element adjustment may also be accomplished by adjusting the relative amounts of the flow reduction element used for allowing flow (more porous 140) or preventing flow (less porous 150).
  • FIG. 3 illustrates a flow reduction element embodiment where more of the flow reduction device is utilized for allowing flow than for preventing flow.
  • FIG. 4 illustrates a flow reduction element embodiment where more of the flow reduction device is utilized for preventing flow than for allowing flow.
  • the foregoing are merely examples. More than one flow allowing or more than one flow preventing zone or portion may be used in a flow reduction element.
  • a device may have flow reduction elements having one or more flow adjustment zones, or no flow adjustment zones.
  • the type of flow reduction elements and the flow characteristics of those flow reduction elements may be mixed within a flow reduction device depending upon the desired flow characteristics desired.
  • Other flow reduction element properties such as the shape and size of a reduction element, the relative size between reduction elements, the alignment or orientation of a reduction element to the central shaft or spine and other properties are further described in the incorporated applications and may also be adjusted to accomplish the nutrient delivery aspects described herein.
  • the flow reduction elements could also be configured to capture and hold a lipid 'pill'.
  • the patient could periodically swallow a lipid 'pill' or other form that engages the device and remains in place.
  • the nutrient could also take the form of an extended release compound that releases an amount of the nutrient over time.
  • the nutrient could also be mixed with another compound that is released when the patient consumes a releasing agent, such as before a meal or at a time of day prone to hunger pangs or higher than desired blood glucose levels.
  • the releasing agent mixes with the nutrient compound mixture causing the release of nutrients, such as lipids, to aid in regulation of hunger and/or glucose.
  • the flow reduction device could be coated with, manufactured with or contain nutrients such as lipids or lipid-philic materials.
  • the flow reduction elements could be one or more bulges manufactured using lipid leaching materials; or the bulges could be manufactured with lipid-philic materials or a sponge like membrane inside the bulges or otherwise connected to the device backbone, that would absorb and distribute temporally lipids from passing ingesta to increase hormonal regulation.
  • the flow reduction elements positioned along the device backbone could be coated with, manufactured from or contain lipid-philic materials.
  • one or more of the flow reduction elements of the intraduodenal device could be manufactured from a lipid absorbing or adsorbing material.
  • a flow reduction element manufactured in this way will attract and collect lipids from passing ingesta and hold the lipids for a period of time.
  • the length of time that the lipids will remain attached to the flow reduction element will vary based on a number of factors.
  • the flow reduction element may exude the lipids as peristalsis continues to squeeze the device.
  • the prolonged presence of and/or sustained release of lipids within the duodenum is believed to benefit and in some cases to increase hormonal regulation. It is to be appreciated that embodiments of the present invention provide prolonged presence of and/or sustained release of lipids within the duodenum through the use of one or more of: making flow reduction elements and/or other components of the flow reduction device (i.e., any of the components of FIG.
  • the spine could be configured as a central tube with plural inlet/outlet ports in communication with a flow reduction element and/or the outside of the tube as described in the incorporated applications.
  • a portion of the device itself i.e.: the backbone or spine, could be hollow such that it could be filled with lipids that would leach out or otherwise be delivered to the duodenum.
  • a nutrient reservoir may be implanted within the patient, within the flow reduction device or separately injected into the device during implantation, after insertion or periodically while the patient has the device inserted in his duodenum.
  • the lipid equipped hormonal regulatory device could be configured to release lipids on demand using an internal or external controller or device as described in U.S. Patent Application No. 11/807,107, filed May 25, 2007, entitled "METHODS AND DEVICES TO CURB APPETITE AND/OR REDUCE FOOD INTAKE," now publication no. 2007-0293885.

Abstract

Cette invention concerne des dispositifs conçus et configurés pour être utilisés à l’intérieur du duodénum d’un mammifère. Un aspect du dispositif comprend une colonne vertébrale ayant une extrémité proximale et une extrémité distale; un élément atraumatique situé sur l’extrémité proximale et/ou l’extrémité distale de la colonne vertébrale; et un élément de réduction du débit situé le long de la colonne vertébrale et dont la porosité varie sur sa longueur. Dans un autre aspect, un dispositif de réduction du débit est conçu et configuré pour être utilisé à l’intérieur du duodénum d’un mammifère, ledit dispositif ayant une colonne vertébrale d’une certaine longueur, une extrémité proximale et une extrémité distale; un premier élément atraumatique situé adjacent à l’extrémité proximale de la colonne vertébrale; un second élément atraumatique situé adjacent à l’extrémité distale de la colonne vertébrale, la longueur de la colonne vertébrale étant telle que lorsque le premier élément atraumatique se trouve dans l’estomac, le second élément atraumatique se trouve dans la quatrième partie du duodénum; et un élément de réduction du débit ayant une extrémité proximale, une extrémité distale, une portion interne, une portion externe, et une porosité variable entre l’extrémité proximale et l’extrémité distale. Par ailleurs ou en variante, une partie ou l’intégralité des composants du dispositif peut être formée à partir d’un matériau lipophile ou recouverte de ce matériau. L’invention concerne aussi une méthode d’ajustement du passage de l’ingesta par le duodénum d’un mammifère. La méthode comprend la mise en place de l’extrémité distale d’un dispositif de réduction du débit dans le duodénum du mammifère; la mise en place de l’extrémité proximale du dispositif de réduction du débit dans l’estomac du mammifère; l’extension à l’intérieur du duodénum du mammifère d’un élément de réduction du débit à porosité variable supporté par le dispositif de réduction du débit; et le guidage d’au moins une partie de l’ingesta le long du duodénum à travers l’extrémité proximale de l’élément de réduction du débit à porosité variable et jusque dans une partie interne de l’élément de réduction du débit à porosité variable.
PCT/US2009/049586 2004-11-30 2009-07-02 Méthodes et dispositifs d’introduction ou de ralentissement de l’introduction des lipides dans le duodénum WO2010003097A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP09774546.7A EP2313034B1 (fr) 2008-07-02 2009-07-02 Dispositifs d'introduction ou de ralentissement des lipides dans le duodénum
BRPI0915286A BRPI0915286A2 (pt) 2008-07-02 2009-07-02 dispositivo adaptado e configurado para uso dentro do duodeno de um mamífero, e, método para ajustar a passagem de ingesta
MX2010014323A MX2010014323A (es) 2008-07-02 2009-07-02 Metodos y dispositivos para suministrar o retardar lipidos dentro de un duodeno.
ES09774546.7T ES2552821T3 (es) 2008-07-02 2009-07-02 Dispositivos para introducir o retrasar lípidos en el duodeno
US12/999,180 US20110137227A1 (en) 2007-07-16 2009-07-02 Methods and devices for delivering or delaying lipids within a duodenum
HK11111552.4A HK1157252A1 (en) 2008-07-02 2011-10-26 Devices for delivering or delaying lipids within a duodenum
US13/769,097 US9072861B2 (en) 2004-11-30 2013-02-15 Methods and devices for delivering or delaying lipids within a duodenum
US14/793,454 US20150305906A1 (en) 2004-11-30 2015-07-07 Methods and devices for delivering or delaying lipids within a duodenum
US15/384,130 US20170156908A1 (en) 2004-11-30 2016-12-19 Methods and devices for delivering or delaying lipids within a duodenum

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7757908P 2008-07-02 2008-07-02
US61/077,579 2008-07-02
PCT/US2008/070226 WO2009012335A1 (fr) 2007-07-16 2008-07-16 Un dispositif intraluminal à conformation stabilisé pour applications médicales
USPCT/US2008/070226 2008-07-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/070226 Continuation-In-Part WO2009012335A1 (fr) 2004-11-30 2008-07-16 Un dispositif intraluminal à conformation stabilisé pour applications médicales

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/999,180 A-371-Of-International US20110137227A1 (en) 2007-07-16 2009-07-02 Methods and devices for delivering or delaying lipids within a duodenum
US13/769,097 Continuation US9072861B2 (en) 2004-11-30 2013-02-15 Methods and devices for delivering or delaying lipids within a duodenum

Publications (2)

Publication Number Publication Date
WO2010003097A2 true WO2010003097A2 (fr) 2010-01-07
WO2010003097A3 WO2010003097A3 (fr) 2011-04-07

Family

ID=41466613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/049586 WO2010003097A2 (fr) 2004-11-30 2009-07-02 Méthodes et dispositifs d’introduction ou de ralentissement de l’introduction des lipides dans le duodénum

Country Status (6)

Country Link
EP (1) EP2313034B1 (fr)
BR (1) BRPI0915286A2 (fr)
ES (1) ES2552821T3 (fr)
HK (1) HK1157252A1 (fr)
MX (1) MX2010014323A (fr)
WO (1) WO2010003097A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315509A (en) 1977-01-10 1982-02-16 Smit Julie A Insertion and removal catheters and intestinal tubes for restricting absorption
US20050049718A1 (en) 2002-11-01 2005-03-03 Valentx, Inc. Gastrointestinal sleeve device and methods for treatment of morbid obesity
US20050192614A1 (en) 2004-02-26 2005-09-01 Binmoeller Kenneth F. Method and apparatus for reducing obesity
US20070156159A1 (en) 2002-10-23 2007-07-05 Jamy Gannoe Method and device for use in endoscopic organ procedures
US20070293885A1 (en) 2004-02-26 2007-12-20 Binmoeller Kenneth F Methods and devices to curb appetite and/or to reduce food intake
WO2009012335A1 (fr) 2007-07-16 2009-01-22 Endosphere, Inc. Un dispositif intraluminal à conformation stabilisé pour applications médicales

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5396880A (en) * 1992-04-08 1995-03-14 Danek Medical, Inc. Endoscope for direct visualization of the spine and epidural space
KR20010052095A (ko) * 1997-11-07 2001-06-25 폴 길슨, 디렉터 색전 보호 장치
US6306163B1 (en) * 1998-08-04 2001-10-23 Advanced Cardiovascular Systems, Inc. Assembly for collecting emboli and method of use
US20070135768A1 (en) * 2005-12-14 2007-06-14 Carlsen Wayne D Spinal and epidural regional anesthesia catheter

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315509A (en) 1977-01-10 1982-02-16 Smit Julie A Insertion and removal catheters and intestinal tubes for restricting absorption
US20070156159A1 (en) 2002-10-23 2007-07-05 Jamy Gannoe Method and device for use in endoscopic organ procedures
US20050049718A1 (en) 2002-11-01 2005-03-03 Valentx, Inc. Gastrointestinal sleeve device and methods for treatment of morbid obesity
US20050192614A1 (en) 2004-02-26 2005-09-01 Binmoeller Kenneth F. Method and apparatus for reducing obesity
US20070293885A1 (en) 2004-02-26 2007-12-20 Binmoeller Kenneth F Methods and devices to curb appetite and/or to reduce food intake
WO2009012335A1 (fr) 2007-07-16 2009-01-22 Endosphere, Inc. Un dispositif intraluminal à conformation stabilisé pour applications médicales

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2313034A4

Also Published As

Publication number Publication date
WO2010003097A3 (fr) 2011-04-07
ES2552821T3 (es) 2015-12-02
BRPI0915286A2 (pt) 2016-02-16
EP2313034B1 (fr) 2015-09-23
EP2313034A2 (fr) 2011-04-27
MX2010014323A (es) 2011-03-03
HK1157252A1 (en) 2012-06-29
EP2313034A4 (fr) 2012-12-12

Similar Documents

Publication Publication Date Title
US20170156908A1 (en) Methods and devices for delivering or delaying lipids within a duodenum
US11607329B2 (en) Intragastric device for treating obesity
KR101268271B1 (ko) 배리애트릭 장치 및 방법
JP4426852B2 (ja) 飽和デバイス及び方法
US8603023B2 (en) Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods
US9872786B2 (en) Gastro-esophageal implants
US8876761B2 (en) Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods
CN101810524B (zh) 饱满装置
EP2967821B1 (fr) Dispositif intragastrique pour traiter l'obésité
EP3329883B1 (fr) Dispositif intragastrique destiné à traiter l'obésité
US20110295178A1 (en) Intestinal Brake Inducing Intraluminal Therapeutic Substance Eluting Devices and Methods
EP2313034B1 (fr) Dispositifs d'introduction ou de ralentissement des lipides dans le duodénum
CN100556477C (zh) 减肥装置和方法
EP2424462B1 (fr) Système d'implant chirurgical à changement de forme ajustable

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/014323

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12999180

Country of ref document: US

Ref document number: 2009774546

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0915286

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101228